Rivaflo 20

Rivaroxaban is an oral direct factor Xa inhibitor anticoagulant that selectively targets free and clot-bound factor Xa, as well as factor Xa within the prothrombinase complex, thereby interrupting the coagulation cascade without affecting thrombin directly.[1] It is primarily indicated for the prophylaxis of deep vein thrombosis in patients undergoing hip or knee replacement surgery, the treatment of deep vein thrombosis and pulmonary embolism, and the reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.[2][3] Unlike vitamin K antagonists such as warfarin, rivaroxaban offers fixed dosing without the need for routine coagulation monitoring, though it carries risks of bleeding that require careful patient selection and management.[2]